On March 17, 2025, Crypto Briefing – a publication known for covering blockchain asset trends – published a bombshell: OpenEvidence, an AI-powered medical platform, is reportedly raising $200 million at a $20 billion valuation. The headline metric: “over 40% of U.S. doctors use the platform.” To the average investor, this smells like the next trillion-dollar opportunity. To an on-chain detective who has spent a decade tracing the silent bleed from 2017’s broken logic, it smells like a DeFi protocol that claims 100,000 daily active users but only has 12 unique wallets interacting with its smart contract.
The pattern is identical: a single, unverifiable number inflated to justify an absurd valuation, amplified by a media outlet whose audience is primed for hype. The lack of audited financials, clear user definitions, or regulatory disclosure is not an oversight – it’s a feature. In crypto, we call this a “pump and dump.” In AI-health, they call it “breakneck growth.” The underlying mechanics are the same.
Context: The Hype Machine Crosses Sectors
OpenEvidence describes itself as an AI-driven clinical decision support tool – a natural-language interface that helps doctors retrieve and synthesize medical knowledge. The company has not released detailed financials, user engagement metrics, or regulatory filings. The only concrete data point comes from the Crypto Briefing report, which itself cites unnamed sources “familiar with the matter.” The report does not specify whether “use” means a single login, a monthly active user, or a paying subscriber. It does not name the investors. It does not reference any peer-reviewed clinical validation or FDA clearance.
In a sideways crypto market where narratives around AI-crossover projects are gaining traction, this kind of leak is perfectly timed. The same playbook was used in 2021 by countless DeFi protocols: announce a massive valuation through a friendly media outlet, create a fear-of-missing-out (FOMO) spiral, and let the hype attract both capital and users. The difference is that DeFi protocols at least have on-chain data – I can trace every transaction, every wallet, every liquidity withdrawal. Here, we have nothing but a press release.
Core: The Forensic Teardown
The Valuation Math Doesn’t Hold Without Revenue. A $20 billion valuation implies that OpenEvidence is worth roughly one-quarter of OpenAI’s reported $80 billion valuation – and OpenAI has a real product (ChatGPT) with proven revenue. Even if OpenEvidence has 400,000 doctor users (40% of roughly 1 million U.S. physicians), that is a user base, not a profit engine. To justify $20 billion, each user would need to generate $50,000 in annual revenue, or the company would need to capture an entire market with astronomical margins. No financial data is provided to support either scenario. In crypto, we see this when a project’s fully diluted valuation (FDV) exceeds $10 billion while its total value locked (TVL) is under $10 million. The ratio is identical: hype over substance.
The 40% Doctor Claim is an On-Chain Red Flag. In my years auditing ICO contracts from 2017, I learned that any project claiming “millions of users” without offering a public, verifiable API or on-chain registry is almost certainly inflating its numbers. The most infamous example was a blockchain gaming project that claimed 2 million users; after a network audit, we discovered 1.8 million were bot addresses. OpenEvidence’s metric is even less verifiable – there is no public dashboard showing unique physician logins, no third-party auditor, no token-gated access list. The number is untestable, and therefore worthless. A responsible investor should demand a clear definition: Are these monthly active users? Are they paying? What is the attrition rate?
The Source is a Contamination Vector. Crypto Briefing is not a health-tech or mainstream financial outlet. It is a niche crypto news website that often runs sponsored content and press releases disguised as news. The fact that an AI health company chose this medium to leak its valuation suggests the target audience is crypto-native investors – precisely the group most susceptible to narrative-driven speculation. This is not a mainstream breakthrough; it is a targeted marketing campaign. I’ve seen the same tactic used by DeFi protocols that paid for coverage on small crypto blogs to manufacture legitimacy before a token sale.
Regulatory Silence is a Black Hole. Any AI tool that influences clinical decisions in the U.S. must comply with HIPAA (patient data privacy) and potentially FDA scrutiny if it qualifies as a medical device. The OpenEvidence report mentions none of this. If the tool is not FDA-cleared, every recommendation it makes carries liability risk for doctors and hospitals. The absence of regulatory discussion is the single biggest red flag – it is equivalent to a DeFi protocol launching without a single smart contract audit. In crypto, we learned the hard way that unaudited code leads to multimillion-dollar hacks. In health, unaudited AI leads to patient harm and lawsuits.
The Data Moat is a Mirage. The narrative argues that OpenEvidence’s proprietary medical dataset creates an unbreachable moat. But AI models are becoming commoditized; a foundation model like GPT-6 could be fine-tuned on public medical literature (PubMed, clinical trial data) and achieve comparable performance without any private data. Data alone is not a moat – the ability to constantly update and verify that data is. The report gives no evidence of a feedback loop where doctors correct AI errors in real time. Without that, OpenEvidence is just a thin wrapper around existing knowledge.
The Timing Screams Market Peak. We are in a sideways market where interest rates remain high and speculative capital is rotating into AI narratives. A $20 billion valuation for a company that has not published a single audited financial statement screams “froth.” In 2021, I watched countless DeFi projects hit multibillion-dollar valuations only to crash to near-zero when the market turned. The code never lies, only the auditors do – but here, there is no code and no auditor. Just a press release.
Contrarian: What the Bulls Might See
Let me stress-test my own skepticism. It is possible that OpenEvidence has genuinely built a product that half a million doctors rely on daily. If each doctor pays $100 per month (a plausible cost for a clinical decision support tool), that yields $60 million in monthly recurring revenue – $720 million annually. At a 10x revenue multiple (typical for high-growth SaaS), the company would be worth $7.2 billion, not $20 billion. To hit $20 billion, revenue would need to be near $2 billion, which would require either much higher pricing or many more users. The bull case would have to assume that OpenEvidence will expand globally, upsell to hospitals, and achieve network effects where more usage improves the model, attracting even more doctors.
I cannot disprove this scenario; I can only point out that no evidence exists to support it. The fact that a crypto news site leaked the story suggests the company is actively fundraising and may be struggling to close the round with mainstream investors. The silence from reputable health-tech analysts is deafening. If the claim were real, Stat News, MedCity News, or the Wall Street Journal would have picked it up within hours. They haven’t.
Takeaway: Wait for the On-Chain Proof
In forensic accounting, we say that the absence of evidence is not evidence of absence, but in crypto, the absence of on-chain data is evidence of deception. OpenEvidence has not provided any public, independently verifiable metric. Until they publish a proof-of-reserves – or at least a signed auditor’s report confirming user counts and revenue – this is a story designed to enrich early insiders at the expense of late-arriving retail investors.
Tracing the silent bleed from 2017’s broken logic leads me to a simple conclusion: the market will inevitably correct this narrative. When the hype cycle peaks, the real numbers will emerge, and the $20 billion will look as fragile as a DeFi token relying on a single liquidity pool. Do not buy the rumor. Wait for the code. Wait for the audit. Wait for the on-chain truth.
